The highly anticipated World CDx Regulatory Affairs & Policy Summit, is set to debut in Boston from June 19-20, 2024.

From tackling the complexities of LDT regulation and navigating the IVDR maze to understanding reimbursement dynamics, this groundbreaking meeting promises to provide clarity and harmonization in the realm of CDx regulation. Attendance is FREE for drug developers and academics, join us to maintain your clinical momentum, streamline submissions, overcome regulatory bottlenecks, and improve patient access to companion diagnostics.

World Class speakers you have the opportunity to learn from:

• Vihanga Pahalawatta, Director – Regulatory Affairs Companion Diagnostics, AbbVie
• Andrea Renninger, Senior Director – CDx Regulatory Affairs, Daiichi Sankyo
• Claudia Dollins, Vice President – Global Regulatory Affairs, GSK
• Debra Rasmussen, Senior Director – Global Regulatory Affairs, Johnson & Johnson
• Dun Liang – Executive Director, Regulatory Affairs, CDx, Loxo@Lilly
• Siddhartha Mathur – Executive Director – Regulatory Affairs, Merck
• Qing Li, Director – Pathology, clinical development, Oncology, Moderna
• Jai Pandey, Global Head – Device Regulatory for In Vitro Diagnostics & Companion Diagnostics, Digital Health, Sanofi

This summit is poised to bring together key stakeholders, including Directors, VPs, and SVPs in Regulation, Policy, Reimbursement, Digital Health, and Companion Diagnostics from leading companies as well as regulatory experts, payers, and developers to bridge the gap with clinical practice and ease regulatory pressures. Download the brochure or secure your free place now!